OUR MISSION
The American Autoimmune Related Diseases Association (AARDA) is dedicated to the eradication of autoimmune diseases and the alleviation of suffering and the socio-economic impact of autoimmunity through initiating, fostering, and facilitating collaboration in the areas of education, public awareness, research, and patient services in an effective, ethical, and efficient manner.

OFFICERS
Chair: Rich Hodge
Vice-Chair: Lilly Stairs
Secretary: Michelle Ouellet
Treasurer: Nona Bear
President & CEO: Molly Murray

BOARD OF DIRECTORS
Mirta Avila Santos
Quardricos Driskell
Indie Lee
Anna Legassie
Dr. Robert Phillips
Linda J. Roelans
Michael Linn
Sloane Salzburg
Scott Selby
Scott Williams

ADVISORS TO THE BOARD OF DIRECTORS
David Bammert  Stephanie Hales  Artie Shelton

SCIENTIFIC ADVISORY BOARD LEADERSHIP
Chair: Betty Diamond, M.D.
I am grateful for the collective autoimmune community and all that is being done for people living with autoimmune disease, their families and care team, and the scientific and medical teams who are working to find better treatments, and ultimately, cures. Despite this year’s significant challenges brought on by the pandemic, this community has come together to support patients and families like never before. I am proud of what we are accomplishing together and the constant innovation taking place across autoimmune awareness, advocacy, education, and research. We look forward to continued collaboration to create a better tomorrow for the autoimmune patients we serve.

Molly Murray, President & CEO
MAJOR CONTRIBUTORS IN FISCAL YEAR 2021

INDIVIDUAL, CORPORATE, AND FOUNDATION DONORS

Contributions $20,000 & over
Anonymous
AbbVie Inc.
Bristol-Myers Squibb Foundation INC
Eli Lilly and Company
Facebook Fundraisers
Genetech, Inc.
Gilead Sciences Inc.
Horizon Therapeutics
Johnson & Johnson Health Care Systems
Momenta Pharmaceuticals, Inc.
Patient-Centered Outcomes Research Institute
Pfizer, Inc.
PhRMA
Silicon Valley Community Foundation
Takeda Pharmaceuticals USA, Inc.

Contributions $5,000 through $19,999
Todd and Kathy Baker Charitable Fund
Biotechnology Innovation Organization
Indie Lee & Co.
Larry and Catalina Koch
Dr. Nat and Jill Linhardt
Robert A. Waller Foundation
The Park Foundation
Raising money for a Cure - Gracie Reed fundraiser

Contributions $1,000 through $4,999
Anonymous
Ann and Scott Barnhouse
Dr. James D. Barrie and Dr. Leslie Ann Momoda
Nona Bear
Judith Bellin
BLR Fund
Jennifer Carmichael
Lori Ann Demple
Mary Deters
Fraser Family Foundation
Great Lakes Center of Rheumatology
Deanna Irving
Lynn and Steve Kieffer
Mary Kimball
Ashley Krokowski and James Aciermo
Casaundra Lindsey
Kellie Martin and Keith Christian
Kathryn Mayer
Diane Moss
Nancy Munis
Victoria Murray
Mythical Entertainment
Phyllis Nazari
Elizabeth Niemeyer
Raising awareness in honor of Cara Lian Lebedda fundraiser
James and Rita Peterson
Caleb Powers
Purple Butterfly Gift Fund
Quad Cities Community Foundation
William and Terri Reid
Anne Remington

Contributions $1,000 through $4,999 Cont'd
Linda and Douglas Robinson
Steven Robinson
Ben Thomas
Linda and Dan Wilhelms
Women of Health Occupations Promoting Education

Contributions $250 through $999
Aizaz Akram
Chris Alford
Anonymous
William Arnett
Joy Berenfield
Darci Berkovich
JeriAnne Berman
Steffi Bokser
James Bookhamer
Dr. John Bornhofen
Teena Cadwell
Christopher Calavia and Suzanne Brown
Janel Carroll
Eli Cheung
Ed and Judy Christian
Katie Cleary
Rachel Coffman
Edward Connolly
Natasha Corrigan
Jeffrey Davenhall
Joan de Milt Boddie
Michael DeItch
Michael DeRosa
William DeRousse
Justine Devlin
Brianna Drake
Andrew and Maryan Dunnet
Alma-Lynn Dupont
Ashley Durrer
Akiva Flesher
Valerie Forstman Charitable Fund
Susan and Chuck Gaalica
John Paul Gilmartin
Connie Goetzel
Jessica Graham
Greatest Commandments Foundation
Mary Sue and John Gunzburger
Nancy Harris
Karen and Jeffrey Hays
Ellen Hipshy
Sharon Jacobs and David Cohen
John and Myrna's Charitable Fund
Betty Jordan
Geoffrey Karmy
Charity Kates
Patrick Kinlan
Suzanne Klein
Amy and Brian Kobishop
Rita Konetzka
Phyllis Krattenmaker
Cecelia Lance
Michael Lebednik

Page 4
Contributions $250 through $999 Cont’d

Naomi M. and Marc D. Levenson Charitable Fund
Jeremy Levine
Lighthouse Financial LLC
Gail and John Maloney
Shannon Marold
Steve Martin
James McGrath
Richard McGrath
Logan McGruder
Cameron and Kelli McPhee
Patrick Milnes
Bruno Moschetta
Patrick Niemeyer
Orkand Family Foundation
William Pace
William Padnos and Margery Kaye
Jinah Parker

U.S. Japan Communications fundraiser
Sravan Reddy-Bezwada
Robin Reich
Janis Reinschmidt
Lori Richardson
Madeline, Melissa and Samantha Ross
RTU Charitable Fund
Jeanne Russell
Randall Rutta
James Ryan
Tamar Rydzinski
Sean Sanders
Marci and Fred Schwartz
Jaclyn and Scott Selby
Jean Paul Sevilla
Christine Smith

Nicolette and Craig Straley
Thomas Surgent
Marie Taylor
Kathleen and Daniel Thornberry
Joanne and Jeff Urbanowski
Lindsay Wagner
Jerry Wald
Joel Wald
Gail and Lois Warden
Barbara and John Wehling
Jennifer Whipple
Carol Lynn White
David Witherspoon
Charles Wofford
Michele Wornow

Major In-Kind Contributors

Context Strategies
IMD Health
River Ridge Corporate Center
Sidley Austin

Payroll Campaigns, Matching Gifts & Online Giving

Ally Financial Inc. Corporate Citizenship
Amazon Smile
American Express
America’s Charities
Bank of America Matching Gifts
Battelle Always Giving
Charities Aid Foundation of America
Charity on Top Foundation Inc.
Charityvest Inc.
Exelon Corporation
Give inLieu Foundation
Good Today
Graham Holdings Company
IBM
Kroger Community Rewards Program
Make My Donation Inc.

My Tribute Gift Foundation, Inc.
Network for Good
Onehope Foundation
Shell Oil Company Foundation
The Blackbaud Giving Fund
The Wonderful Company Foundation Inc.
Trustees of American Express Foundation
United Way of Central and Northeastern Connecticut
United Way of Central New Mexico
United Way of Greater Philadelphia & Southern New Jersey
Verizon Matching Gifts
Walt Disney Company Foundation Employee Matching Gifts Program

Other Contributors and Friends

Space does not allow us to include the names of all persons and organizations who gave their financial support to AARDA, but we say “Thank You” again as we give this recognition in honor of their generosity.

Memorials and Tributes

Since it is our policy not to release amounts given for these contributions, we take this opportunity to express our appreciation again to all the kind donors. Every contribution has been acknowledged to the donors, to those persons honored, and to the families of those held in memory.
MAJOR ACCOMPLISHMENTS
DURING FISCAL YEAR 2021

ADVOCACY

Let My Doctors Decide

AARDA continues to lead Let My Doctors Decide (LMDD), a national partnership of leaders across health care working in support of a simple goal: treatment decisions should always be made by patients and trusted health care professionals, not insurance companies or pharmacy benefit managers. LMDD launched a Drop the Barriers campaign that calls out the top 10 barriers to care that patients experience, including a patient-focused explainer video. AARDA and LMDD continues to leverage this unique message, driven by a task force of patient and provider groups, to shine a spotlight on the barriers patients face daily.

National Briefing

In July, AARDA hosted Barriers to Improved Health In the Era of COVID-19: Advocates and Providers Speak Out, where patient advocates, providers and health care experts discussed the harm posed by access restrictions.

National Coalition of Autoimmune Patient Groups (NCAPG)

The NCAPG has significantly grown the past year, adding over 10 new organizations that increase representation of autoimmune disease states across the globe. This year, the NCAPG met with congressional offices, members of the CDC COVID-19 Response Team, and leading researchers in Long COVID. The growth and impact of the NCAPG magnifies the voice of patients living with autoimmune disease and addresses key issues of importance to people living with autoimmune disease and their families.
AWARENESS

AARDA continues to lead the way in public awareness for autoimmune and related diseases. In March, we celebrated Autoimmune Disease Awareness Month. This year, we were honored to team up with clean beauty maven Indie Lee and patient influencers to raise widespread awareness about what it means to live with an autoimmune disease. The grassroots campaign, Faces of Autoimmunity, featured the journeys of people living with autoimmune disease. We are grateful to Indie’s team and the inspiring patients, partners, and contributors that emphasized the message that no patient is alone on their journey.

EDUCATION

The long-anticipated approval of the first COVID-19 vaccines brought hope to many people living with autoimmune disease across the globe. At the same time, with misinformation and feelings of uncertainty ever rising, AARDA mobilized a team of experts to ensure that autoimmune patients and their families had access to the latest information on COVID-19 vaccines. In February, AARDA debuted a first-of-its-kind newscast, COVID-19 Vaccines and Autoimmunity, featuring perspectives from the CDC’s COVID-19 Vaccine Task Force, patient advocates, and renowned physicians and researchers. The urgent need for real-time information was clear by the thousands of individuals that tuned in from across the globe. As new information on the COVID-19 vaccine became available, AARDA kept the autoimmune community up to date through speaking engagements, publications, social media, and our COVID-19 Resource Page.
AARDA hosted the 15th Noel Rose Scientific Colloquium on May 1, 2021, bringing together high-level researchers from different specialties to discuss the intersection of COVID-19 and autoimmunity. Participants heard directly from leading autoimmune experts, who shared how their past work on autoimmune diseases helped them pivot to study, understand, and generate hypotheses on how to combat the novel coronavirus. Experts agreed that there is a high degree of overlap between the study of autoimmune diseases and COVID-19 and affirmed their commitment to both a collaborative and holistic approach to the study of autoimmune diseases and COVID-19. As a direct result of the colloquium, a research paper was published in the Journal of Clinical Investigation (JCI), The intersection of COVID-19 and autoimmunity.

Inflammation & Immunophysiology: An Exploration of Pathophysiology Webinar Series

AARDA partnered with the American Physiological Society (APS) and InsideScientific to bring a series of six webinars to thousands of global participants in the scientific community, covering fundamental principles, late-breaking research, and novel discoveries in the field of inflammation and immunophysiology. The series included live lectures from leading researchers around the world and “Technology & Methods” sessions focused on laboratory innovations and fundamental methods central to immunology and inflammation research and related models of disease.
RA Research Results Funded by the Virginia T. Ladd Young Investigator Program

Dr. Tarun Sharma, a rheumatologist from the Allegheny Health Network in Pittsburgh, is a recipient of a research grant from the Virginia T. Ladd Young Investigator Program. Dr. Sharma’s research looked at the best strategy for tapering treatment with biologics and non-biological RA medications to treatments with less risk in well-controlled RA patients to maximize the wellbeing of the patient has been a long-standing concern for both physician and patient. The practice-based study was conducted over a two-year period. The study shed light on the chances of a flare of RA with different tapering strategies and attempts to predict which patients might be good candidates for medication tapering. The study results concluded that tapering of both biologics and non-biologics together led to higher odds of flares. However, Dr. Sharma found that in cases where a flare occurred, resuming the previous treatment regimen led to disease control within 2-3 months. The findings help both physician and patient decision making by being better informed and able to participate in shared decisions regarding what is the most suitable long-term therapy strategy for individual patients with RA.

We congratulate Dr. Sharma and all Virginia T. Ladd Young Investigator Program awardees for their excellent investigation in autoimmune disease, and we encourage other young investigators to focus their research in this growing area where there is much opportunity and new discoveries waiting to be explored.
The Board of Directors,

American Autoimmune Related Diseases Association
Clinton Township, Michigan

We have audited the accompanying financial statements of American Autoimmune Related Diseases Association (a nonprofit organization) which comprise the statement of financial position as of September 30, 2021, and the related statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the financial statements.

Management’s Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor’s Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, based on our audit, the financial statements referred to above present fairly, in all material respects, the financial position of American Autoimmune Related Diseases Association as of September 30, 2021, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

April 25, 2022
## Revenue and Other Support

<table>
<thead>
<tr>
<th>Description</th>
<th>WITHOUT DONOR RESTRICTIONS</th>
<th>WITH DONOR RESTRICTIONS</th>
<th>2020 TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>$2,645,294</td>
<td>$634,124</td>
<td>$3,279,418</td>
</tr>
<tr>
<td>Paycheck Protection Program grant</td>
<td>123,400</td>
<td></td>
<td>123,400</td>
</tr>
<tr>
<td>In-kind goods and services</td>
<td>482,143</td>
<td>0</td>
<td>482,143</td>
</tr>
<tr>
<td>Fundraising income - net of expenses of $0</td>
<td>3,398</td>
<td>0</td>
<td>3,398</td>
</tr>
<tr>
<td>Other income</td>
<td>2,285</td>
<td>0</td>
<td>2,285</td>
</tr>
<tr>
<td>Interest income</td>
<td>2,463</td>
<td>0</td>
<td>2,463</td>
</tr>
<tr>
<td><strong>Net assets released from restrictions</strong></td>
<td>586,924</td>
<td>(586,924)</td>
<td>0</td>
</tr>
<tr>
<td><strong>Total Revenue and Other Support</strong></td>
<td><strong>3,845,907</strong></td>
<td><strong>47,200</strong></td>
<td><strong>3,893,107</strong></td>
</tr>
</tbody>
</table>

## Expenses

### Program services

<table>
<thead>
<tr>
<th>Description</th>
<th>WITHOUT DONOR RESTRICTIONS</th>
<th>WITH DONOR RESTRICTIONS</th>
<th>2020 TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Education</td>
<td>966,873</td>
<td>0</td>
<td>966,873</td>
</tr>
<tr>
<td>Public awareness</td>
<td>2,217,156</td>
<td>0</td>
<td>2,217,156</td>
</tr>
<tr>
<td>Research</td>
<td>191,194</td>
<td>0</td>
<td>191,194</td>
</tr>
<tr>
<td><strong>Total program services</strong></td>
<td><strong>3,375,222</strong></td>
<td>0</td>
<td><strong>3,375,222</strong></td>
</tr>
</tbody>
</table>

### Supporting services

<table>
<thead>
<tr>
<th>Description</th>
<th>WITHOUT DONOR RESTRICTIONS</th>
<th>WITH DONOR RESTRICTIONS</th>
<th>2020 TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Management and general</td>
<td>104,058</td>
<td>0</td>
<td>104,058</td>
</tr>
<tr>
<td>Fundraising</td>
<td>61,708</td>
<td>0</td>
<td>61,708</td>
</tr>
<tr>
<td><strong>Total supporting services</strong></td>
<td><strong>165,766</strong></td>
<td>0</td>
<td><strong>165,766</strong></td>
</tr>
</tbody>
</table>

**Total Expenses**

<table>
<thead>
<tr>
<th>Description</th>
<th>WITHOUT DONOR RESTRICTIONS</th>
<th>WITH DONOR RESTRICTIONS</th>
<th>2020 TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Expenses</strong></td>
<td><strong>3,540,988</strong></td>
<td>0</td>
<td><strong>3,540,988</strong></td>
</tr>
</tbody>
</table>

## Change in Net Assets

<table>
<thead>
<tr>
<th>Description</th>
<th>WITHOUT DONOR RESTRICTIONS</th>
<th>WITH DONOR RESTRICTIONS</th>
<th>2020 TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net Assets, Beginning of Year</strong></td>
<td><strong>$912,080</strong></td>
<td><strong>$364,786</strong></td>
<td><strong>$1,276,866</strong></td>
</tr>
<tr>
<td><strong>Net Assets, End of Year</strong></td>
<td><strong>$1,216,999</strong></td>
<td><strong>$411,986</strong></td>
<td><strong>$1,628,985</strong></td>
</tr>
</tbody>
</table>
## STATEMENT OF FUNCTIONAL EXPENSES

For the Year Ended September 30, 2021

<table>
<thead>
<tr>
<th>Program Services</th>
<th>Total Program Services</th>
<th>Supporting Services</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Education</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$265,002</td>
<td></td>
<td>$31,018</td>
<td>$257,400</td>
</tr>
<tr>
<td><strong>Public Awareness</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$347,709</td>
<td></td>
<td>1,755</td>
<td>$70,328</td>
</tr>
<tr>
<td><strong>Research</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$87,757</td>
<td></td>
<td>7,100</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$700,468</td>
<td>$3,375,222</td>
<td>$3,540,988</td>
</tr>
<tr>
<td><strong>Supporting Services</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Management and General</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$28,646</td>
<td></td>
<td>10,916</td>
<td></td>
</tr>
<tr>
<td>Professional fees</td>
<td></td>
<td>1,545</td>
<td></td>
</tr>
<tr>
<td>Postage/shipping</td>
<td></td>
<td>246</td>
<td></td>
</tr>
<tr>
<td>Public relations</td>
<td></td>
<td>114,662</td>
<td></td>
</tr>
<tr>
<td>Legal</td>
<td>$103,696</td>
<td>12,846</td>
<td></td>
</tr>
<tr>
<td>Consulting services</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grant writing</td>
<td>$5,566</td>
<td>237</td>
<td></td>
</tr>
<tr>
<td>Printing/stationery</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Office supplies</td>
<td>$1,212</td>
<td>10,163</td>
<td></td>
</tr>
<tr>
<td>Operating supplies</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dues/subscriptions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Filing fees</td>
<td>$9,566</td>
<td>66,877</td>
<td></td>
</tr>
<tr>
<td>Planned giving</td>
<td>$2,908</td>
<td>6,781</td>
<td></td>
</tr>
<tr>
<td>Rent</td>
<td>$2,258</td>
<td>100,766</td>
<td></td>
</tr>
<tr>
<td>Equipment maintenance</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Telephone</td>
<td>$2,815</td>
<td>360</td>
<td></td>
</tr>
<tr>
<td>Insurance</td>
<td>$983</td>
<td>237</td>
<td></td>
</tr>
<tr>
<td>State/national meetings</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Travel</td>
<td>$985</td>
<td>2,488</td>
<td></td>
</tr>
<tr>
<td>Depreciation</td>
<td>$2,243</td>
<td>5,315</td>
<td></td>
</tr>
<tr>
<td>Payroll taxes</td>
<td>$2,258</td>
<td>140</td>
<td></td>
</tr>
<tr>
<td>Insurance - Health</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fundraising - Other</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Board expenses</td>
<td>$2,258</td>
<td>140</td>
<td></td>
</tr>
<tr>
<td>Events</td>
<td>$2,258</td>
<td>140</td>
<td></td>
</tr>
<tr>
<td>Professional training</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grants</td>
<td>$2,258</td>
<td>140</td>
<td></td>
</tr>
<tr>
<td>Repairs/maintenance</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Utilities</td>
<td>$2,258</td>
<td>140</td>
<td></td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>$2,258</td>
<td>140</td>
<td></td>
</tr>
<tr>
<td>Retirement plan contributions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Website</td>
<td>$2,258</td>
<td>140</td>
<td></td>
</tr>
<tr>
<td>Advertising/development</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total Expenses by Function</strong></td>
<td>$966,873</td>
<td>$2,217,156</td>
<td>$191,194</td>
</tr>
</tbody>
</table>

Less expenses included with revenues on the statement of activities

<table>
<thead>
<tr>
<th>Education</th>
<th>Public Awareness</th>
<th>Research</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Total expenses included in the expense section on the statement of activities

<table>
<thead>
<tr>
<th>Education</th>
<th>Public Awareness</th>
<th>Research</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>$966,873</td>
<td>$2,217,156</td>
<td>$191,194</td>
<td>$3,375,222</td>
</tr>
</tbody>
</table>